[Form 4] Tyra Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Tyra Biosciences insider purchase under ESPP: The company's Chief Financial Officer, Alan Fuhrman, acquired 701 shares of Tyra Biosciences common stock on 09/15/2025 at a purchase price of $9.129 per share under the issuer's 2021 Employee Stock Purchase Plan. After the transaction, Mr. Fuhrman beneficially owned 14,788 shares. The Form 4 was signed by an attorney-in-fact on 09/17/2025.

Positive

• Insider purchase under ESPP indicates the CFO participated in the company's employee purchase plan
• Timely disclosure filed and signed by attorney-in-fact within two days of the transaction date

Negative

• None.

Insights

Financial Analyst

TL;DR CFO purchased a small number of shares via the ESPP, increasing personal ownership to 14,788 shares.

The purchase of 701 shares at $9.129 under the 2021 Employee Stock Purchase Plan represents a routine, non-discretionary employee plan transaction rather than a large, strategic insider buy. The transaction size is modest relative to typical market-moving insider purchases, and the filing shows no sales or derivative activity reported concurrently. This is a limited signal of management alignment but not materially impactful on valuation.

Corporate Governance Expert

TL;DR Disclosure is timely and follows Section 16 reporting; transaction arises from an established ESPP.

The Form 4 discloses the CFO's acquisition through the company ESPP and provides required details: transaction date, price, number of shares, and post-transaction beneficial ownership. The filing was executed by an attorney-in-fact and includes the explanatory note that the shares were acquired under the 2021 Employee Stock Purchase Plan. No governance concerns or deviations from standard Section 16 reporting appear in the document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Fuhrman Alan

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		A(1)	V	701	A	$9.129	14,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

	/s/ Ali D. Fawaz, Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tyra Biosciences (TYRA) insider Alan Fuhrman report on Form 4?

The Form 4 reports that CFO Alan Fuhrman acquired 701 shares of Tyra Biosciences common stock on 09/15/2025 at $9.129 per share under the 2021 Employee Stock Purchase Plan, resulting in beneficial ownership of 14,788 shares.

How were the shares acquired according to the filing?

The filing states the shares were acquired under the issuer's 2021 Employee Stock Purchase Plan.

When was the Form 4 signed and by whom?

The Form 4 signature block shows it was signed by Ali D. Fawaz, Attorney-in-Fact on 09/17/2025.

Does the Form 4 report any derivative transactions or dispositions?

No. The filing reports a non-derivative acquisition of common stock and shows no derivative securities or dispositions.

What is the post-transaction beneficial ownership reported?

Post-transaction beneficial ownership is reported as 14,788 shares.